TL-118 is an oral solution that targets different, non-overlapping aspects of the angiogenic process, inhibiting new blood vessel formations in tumors.
The trial will include 80 patients with newly diagnosed metastatic pancreatic cancer that have not yet been treated with chemotherapy.
Following an approval by the Israeli Ministry of Health, Tiltan Pharma has initiated the Phase 2 study of TL-118 in major oncology centers in Israel.
Simultaneously, the company is evaluating TL-118 for the treatment of prostate cancer.
In pre-clinical trials, TL-118 monotherapy and in combination with the standard-of-care chemotherapy has been found to suppress tumor growth in all treated animals.
Prior Phase I clinical trial conducted at Tel-Hashomer, Israel, also demonstrated the safety and tolerability of TL-118 for treating cancer patients.